118 related articles for article (PubMed ID: 11585252)
1. p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance: an analysis of 103 cases.
Korshunov A; Golanov A; Timirgaz V
Acta Neuropathol; 2001 Sep; 102(3):271-7. PubMed ID: 11585252
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical markers for prognosis of ependymal neoplasms.
Korshunov A; Golanov A; Timirgaz V
J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
Korshunov A; Golanov A; Timirgaz V
J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
5. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
[TBL] [Abstract][Full Text] [Related]
6. p53 gene status and expression of p53, MDM2, and p14 proteins in ameloblastomas.
Kumamoto H; Izutsu T; Ohki K; Takahashi N; Ooya K
J Oral Pathol Med; 2004 May; 33(5):292-9. PubMed ID: 15078490
[TBL] [Abstract][Full Text] [Related]
7. Proliferation- and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis.
Verstegen MJ; Leenstra DT; Ijlst-Keizers H; Bosch DA
J Neurooncol; 2002 Jan; 56(1):21-8. PubMed ID: 11949823
[TBL] [Abstract][Full Text] [Related]
8. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors.
Eymin B; Gazzeri S; Brambilla C; Brambilla E
Oncogene; 2002 Apr; 21(17):2750-61. PubMed ID: 11965548
[TBL] [Abstract][Full Text] [Related]
9. p53 Pathway dysfunction in primary childhood ependymomas.
Gaspar N; Grill J; Geoerger B; Lellouch-Tubiana A; Michalowski MB; Vassal G
Pediatr Blood Cancer; 2006 May; 46(5):604-13. PubMed ID: 16086408
[TBL] [Abstract][Full Text] [Related]
10. The growth potential of ependymomas with varying grades of malignancy measured by the Ki-67 labelling index and mitotic index.
Schröder R; Ploner C; Ernestus RI
Neurosurg Rev; 1993; 16(2):145-50. PubMed ID: 8345908
[TBL] [Abstract][Full Text] [Related]
11. [Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma].
Yu GZ; Zhu MH; Ni CR; Li FM; Zheng JM; Gong ZJ
Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):130-4. PubMed ID: 15132849
[TBL] [Abstract][Full Text] [Related]
12. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
13. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
[TBL] [Abstract][Full Text] [Related]
14. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
[TBL] [Abstract][Full Text] [Related]
15. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype.
Suri VS; Tatke M; Singh D; Sharma A
Indian J Cancer; 2004; 41(2):66-71. PubMed ID: 15318011
[TBL] [Abstract][Full Text] [Related]
16. Amplification and overexpression of mdm2 gene in ependymomas.
Suzuki SO; Iwaki T
Mod Pathol; 2000 May; 13(5):548-53. PubMed ID: 10824927
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases.
Korshunov A; Sycheva R; Timirgaz V; Golanov A
J Neurooncol; 1999; 45(3):219-27. PubMed ID: 10845392
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of p18INK4C and p14ARF protein expression in 117 oligodendrogliomas: correlation with tumor grade and clinical outcome.
Korshunov A; Golanov A
Arch Pathol Lab Med; 2002 Jan; 126(1):42-8. PubMed ID: 11800646
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas.
Suzuki S; Oka H; Kawano N; Tanaka S; Utsuki S; Fujii K
Brain Tumor Pathol; 2001; 18(2):151-4. PubMed ID: 11908872
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma.
Wolfsberger S; Fischer I; Höftberger R; Birner P; Slavc I; Dieckmann K; Czech T; Budka H; Hainfellner J
Am J Surg Pathol; 2004 Jul; 28(7):914-20. PubMed ID: 15223962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
